相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non-Small Cell Lung Cancer
George R. Blumenschein et al.
CLINICAL CANCER RESEARCH (2010)
TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives
J. H. Stegehuis et al.
DRUG RESISTANCE UPDATES (2010)
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities
Michelle Head et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
Cesare Gridelli et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
BIBF 1120 for the treatment of non-small cell lung cancer
Martin Reck
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia
Gary J. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
M. J. Boyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor
Ken Takezawa et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape
Sumanta Kumar Pal et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients
V. Ludovini et al.
ANNALS OF ONCOLOGY (2009)
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2009)
Modulation of Hsf1 activity by novobiocin and geldanamycin
Renaud Conde et al.
BIOCHEMISTRY AND CELL BIOLOGY (2009)
Targeting HSP90 for cancer therapy
D. Mahalingam et al.
BRITISH JOURNAL OF CANCER (2009)
被撤回的出版物: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012)
Daniel D. Karp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin
Daniel D. Karp et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
Kentaro Inamura et al.
MODERN PATHOLOGY (2009)
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Troy A. Luster et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer.
Adi F. Gazdar
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma.
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Nathan A. Pennell et al.
ONCOLOGIST (2009)
A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes
A. Yada et al.
ANNALS OF ONCOLOGY (2008)
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma
Dan J. Raz et al.
CLINICAL CANCER RESEARCH (2008)
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers
Sarat Chandarlapaty et al.
CLINICAL CANCER RESEARCH (2008)
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung
Marcin Skrzypski et al.
CLINICAL CANCER RESEARCH (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Targeting blood vessels for the treatment of non-small cell lung cancer
Ethan Amir et al.
CURRENT CANCER DRUG TARGETS (2008)
Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide-binding Pocket
Alison Donnelly et al.
CURRENT MEDICINAL CHEMISTRY (2008)
IGF2: Epigenetic regulation and role in development and disease
Wendy Chao et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2008)
TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
Andrew Thorburn et al.
DRUG RESISTANCE UPDATES (2008)
DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design
Vicente Tur et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Gregory J. Riely
JOURNAL OF THORACIC ONCOLOGY (2008)
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
F. Anthony Greco et al.
LUNG CANCER (2008)
DHPLC analysis of adenomatous polyposis coli (APC) mutations using ready-to-use APC plates:: Simple detection of multiple base pair deletion mutations
Il-Jin Kim et al.
GENETIC TESTING (2008)
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
David R. Clemmons
NATURE REVIEWS DRUG DISCOVERY (2007)
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
Arthur Edwards et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Who should be sent for genetic testing in hereditary colorectal cancer syndromes?
Henry T. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer
Maureen Cronin et al.
CLINICAL CHEMISTRY (2007)
Wnt inhibitory factor inhibits lung cancer cell growth
Jae Kim et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2007)
A five-gene signature and clinical outcome in non-small-cell lung cancer
Hsuan-Yu Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
Catherine A. O'Brien et al.
NATURE (2007)
Identification and expansion of human colon-cancer-initiating cells
Lucia Ricci-Vitiani et al.
NATURE (2007)
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Lecia V. Sequist
ONCOLOGIST (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mining the Wnt pathway for cancer therapeutics
Nick Barker et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Targeted therapy in advanced non-small cell lung cancer (NSCLC): Where do we stand?
Hatem A. Azim et al.
CANCER TREATMENT REVIEWS (2006)
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer
Ling Geng et al.
CANCER RESEARCH (2006)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Jeffrey A. Engelman et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2006)
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-α
DM Fath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Targeting insulin-like growth factor pathways
D Yee
BRITISH JOURNAL OF CANCER (2006)
Proteasome inhibitors in lung cancer
Giorgio Scagliotti
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis
Y Zhang et al.
CELL DEATH AND DIFFERENTIATION (2006)
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
M MacFarlane et al.
CANCER RESEARCH (2005)
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
Y Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand
F Fang et al.
ACTA PHARMACOLOGICA SINICA (2005)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
QB She et al.
CANCER CELL (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
M Taron et al.
CLINICAL CANCER RESEARCH (2005)
Molecular interactions of the IGF system
A Denley et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Wnt signaling in stem cells and non-small-cell lung cancer
Biao He et al.
CLINICAL LUNG CANCER (2005)
Wnt signaling through canonical and non-canonical pathways: Recent progress
R Widelitz
GROWTH FACTORS (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution
RF Kelley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
KH Emami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
H Jin et al.
CANCER RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
PI3K-Akt pathway: Its functions and alterations in human cancer
M Osaki et al.
APOPTOSIS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex
M Lepourcelet et al.
CANCER CELL (2004)
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression
K Uematsu et al.
ONCOGENE (2003)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
Basement membranes: Structure, assembly and role in tumour angiogenesis
R Kalluri
NATURE REVIEWS CANCER (2003)
Structure and dynamic behavior of nucleosomes
K Luger
CURRENT OPINION IN GENETICS & DEVELOPMENT (2003)
Natural Product Origins of Hsp90 Inhibitors
Yoshimasa Uehara
CURRENT CANCER DRUG TARGETS (2003)
Defining characteristics of Types I and II apoptotic cells in response to TRAIL
N Özören et al.
NEOPLASIA (2002)
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved
G Pandini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis
SY Park et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
S Frese et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2002)
Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α
DA Elson et al.
GENES & DEVELOPMENT (2001)
Histone acetylation and chromatin remodeling
PD Gregory et al.
EXPERIMENTAL CELL RESEARCH (2001)
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
MS Kim et al.
NATURE MEDICINE (2001)
The human histone deacetylase family
SG Gray et al.
EXPERIMENTAL CELL RESEARCH (2001)
Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-mediated transcription
SQ Chen et al.
JOURNAL OF CELL BIOLOGY (2001)
Wnt/β-catenin signaling
T Akiyama
CYTOKINE & GROWTH FACTOR REVIEWS (2000)
New combinations in the treatment of lung cancer - A time for optimism
PA Bunn et al.
CHEST (2000)
The language of covalent histone modifications
BD Strahl et al.
NATURE (2000)
分享论文
